Print Page | Contact Us | Sign In | Join
Medication Safety Webinar
Tell a Friend About This EventTell a Friend
 

9/10/2019
When: Tuesday, September 10, 2019
12:00 PM
Where: United States
Contact: Gaby Webster
978-364-5035


Online registration is closed.
« Go to Upcoming Event List  

Please join us for our Quarterly Medication Safety Webinar! We will be offering CE credits for this webinar, so registration is required. 

Introduction to Postmarketing Drug Safety Surveillance

This activity will introduce practicing pharmacists to pharmacovigilance and explain its role in the advancement of public health. Specifically, information will be shared to help improve the quality of reports received directly from healthcare professionals such as pharmacists.

Learning Objectives: 

  • Define pharmacovigilance and explain its role in the advancement of public health.
  • List two limitations of premarketing clinical trials leading to the inability to describe the full safety profile of a medication.
  • List two potential data sources that might identify a postmarketing safety signal in need of further analysis.
  • Describe the role of a pharmacist in improving the quality of adverse event reports submitted to the MedWatch program.

Speaker

Kelly Harbourt, PharmD, BCCCP
Safety Evaluator
Division of Pharmacovigilance, Office of Surveillance and Epidemiology
Center for Drug Evaluation and Research, FDA

Kelly completed her PharmD at the University of North Carolina at Chapel Hill and went on to complete two years of residency training at VCU Health System in Richmond, VA, where she specialized in Critical Care.  She was the Clinical Pharmacy Specialist in the Adult ICU at Saint Agnes Hospital in Baltimore for two years after completing residency training.  She then took a position as an Assistant Professor in the School of Pharmacy at Notre Dame of Maryland University in Baltimore with a practice site in the Multitrauma ICU at the Shock Trauma Center at the University of Maryland Medical Center.  Kelly also recently completed a three-year term as an MSHP Board member and remains an active member of MSHP.  She has been with the Division of Pharmacovigilance at the FDA for two years and has developed a passion for improving the quality of adverse event reports submitted via the MedWatch program and is excited to share some information with you to help you improve patient safety and advance public health.